Clinically qualifying predictive biomarkers of response to PARPi in patients with prostate cancer

by VHIO

PARP inhibitors (PARPi) are approved for treating advanced prostate cancers with various defective DNA repair genes, although not all patients derive the same benefit from this targeted therapy.

Read more

Genetic gene mutations: opening new therapeutic avenues in metastatic prostate cancer

by Vall d’Hebron

DNA-repair gene mutations are found inherited in one out of every ten men with metastatic prostate cancer. International study shows the prognostic and predictive value of these mutations in more prec...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

A dietary supplement has beneficial effe...

by Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)

Research led by IIBB-CSIC and CIBEREHD scientists identifies S-adenosy...

Photos Stream